The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
MYC and Breast Cancer
Open accessAbstract
MYC is a key regulator of cell growth, proliferation, metabolism, differentiation, and apoptosis. MYC deregulation contributes to breast cancer development and progression and is associated with poor outcomes. Multiple mechanisms are involved in MYC deregulation in breast cancer, including gene amplification, transcriptional regulation, and mRNA and protein stabilization, which correlate with loss of tumor suppressors and activation of oncogenic pathways. The heterogeneity in breast cancer is increasingly recognized. Breast cancer has been classified into 5 or more subtypes based on gene expression profiles, and each subtype has distinct biological features and clinical outcomes. Among these subtypes, basal-like tumor is associated with a poor prognosis and has a lack of therapeutic targets. MYC is overexpressed in the basal-like subtype and may serve as a target for this aggressive subtype of breast cancer. Tumor suppressor BRCA1 inhibits MYC's transcriptional and transforming activity. Loss of BRCA1 with MYC overexpression leads to the development of breast cancer-especially, basal-like breast cancer. As a downstream effector of estrogen receptor and epidermal growth factor receptor family pathways, MYC may contribute to resistance to adjuvant therapy. Targeting MYC-regulated pathways in combination with inhibitors of other oncogenic pathways may provide a promising therapeutic strategy for breast cancer, the basal-like subtype in particular.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
Massagué, J., Seoane, J., & Wotton, D. (2005) · Genes & Development · doi:10.1101/gad.1350705 · Cited by 2,452
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., Teruya-Feldstein, J., Reinhardt, F., Onder, T. T., Valastyan, S., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2024 · Cited by 1,336
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
BRCA1 Mutations in Primary Breast and Ovarian Carcinomas
Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., et al. (1994) · Science · doi:10.1126/science.7939630 · Cited by 1,205
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,131
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Self-citationAntibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Direct activation of TERT transcription by c-MYC
Wu, K.-J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., & Dalla-Favera, R. (1999) · Nature Genetics · doi:10.1038/6010 · Cited by 893
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Askew, D. S., Ashmun, R. A., Simmons, B. C., & Cleveland, J. L. (1991) · PubMed · Cited by 867
A Ligand-Induced Extracellular Cleavage Regulates γ-Secretase-like Proteolytic Activation of Notch1
Mumm, J. S., Schroeter, E. H., Saxena, M. T., Griesemer, A., Tian, X., Pan, D. J., Ray, W. J., & Kopan, R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80416-5 · Cited by 853
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., Lockwood, G., & Egan, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1069 · Cited by 783
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743
Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell Hybridomas
Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., & Green, D. R. (1992) · Science · doi:10.1126/science.1378649 · Cited by 695
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Myc deletion rescues Apc deficiency in the small intestine
Sansom, O. J., Meniel, V. S., Muncan, V., Phesse, T. J., Wilkins, J. A., Reed, K. R., Vass, J. K., Athineos, D., Clevers, H., & Clarke, A. R. (2007) · Nature · doi:10.1038/nature05674 · Cited by 613
Aberrant Activation of Notch Signaling in Human Breast Cancer
Stylianou, S., Clarke, R. B., & Brennan, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3054 · Cited by 562
van de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
Baudino, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., & Cleveland, J. L. (2002) · Genes & Development · doi:10.1101/gad.1024602 · Cited by 525
Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., Goga, A., Balakrishnan, A., Semeraro, M., Gresh, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.002 · Cited by 509
Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., Olopade, O. I., & Goss, K. H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091125 · Cited by 509
Self-citationHoffman, B., & Liebermann, D. A. (2008) · Oncogene · doi:10.1038/onc.2008.312 · Cited by 488
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis
Pece, S., Serresi, M., Santolini, E., Capra, M., Hulleman, E., Galimberti, V., Zurrida, S., Maisonneuve, P., Viale, G., & Di Fiore, P. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200406140 · Cited by 483
Basal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 478
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
Ras Enhances Myc Protein Stability
Sears, R., Leone, G., DeGregori, J., & Nevins, J. R. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80308-1 · Cited by 460
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
Escot, C., Theillet, C., Lidereau, R., Spyratos, F., Champeme, M. H., Gest, J., & Callahan, R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4834 · Cited by 412
Menssen, A., & Hermeking, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082005599 · Cited by 406
The APC tumor suppressor counteracts β-catenin activation and H3K4 methylation at Wnt target genes
Sierra, J., Yoshida, T., Joazeiro, C. A., & Jones, K. A. (2006) · Genes & Development · doi:10.1101/gad.1385806 · Cited by 385
Foulkes, W. D., Brunet, J.-S., Stefansson, I. M., Straume, O., Chappuis, P. O., Bégin, L. R., Hamel, N., Goffin, J. R., Wong, N., Trudel, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2970 · Cited by 363
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
Newman, B. (1998) · JAMA · doi:10.1001/jama.279.12.915 · Cited by 345
Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor
Levin, E. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0368 · Cited by 329
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells
Bafico, A., Liu, G., Goldin, L., Harris, V., & Aaronson, S. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.032 · Cited by 324
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
Chen, C.-R., Kang, Y., & Massagué, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.992 · Cited by 320
Wu, S., Cetinkaya, C., Munoz-Alonso, M. J., von der Lehr, N., Bahram, F., Beuger, V., Eilers, M., Leon, J., & Larsson, L.-G. (2003) · Oncogene · doi:10.1038/sj.onc.1206145 · Cited by 317
A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size
Welcker, M., Orian, A., Grim, J. A., Eisenman, R. N., & Clurman, B. E. (2004) · Current Biology · doi:10.1016/j.cub.2004.09.083 · Cited by 312
Vennstrom, B., Sheiness, D., Zabielski, J., & Bishop, J. M. (1982) · Journal of Virology · doi:10.1128/jvi.42.3.773-779.1982 · Cited by 307
Fulford, L. G., Reis-Filho, J. S., Ryder, K., Jones, C., Gillett, C. E., Hanby, A., Easton, D., & Lakhani, S. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1636 · Cited by 306
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
Deming, S. L., Nass, S. J., Dickson, R. B., & Trock, B. J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1522 · Cited by 302
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Mechanism of estrogen activation of c-myc oncogene expression.
Dubik, D., & Shiu, R. P. C. (1992) · PubMed · Cited by 294
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
Banerjee, S., Reis-Filho, J. S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. R., & Smith, I. E. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.033043 · Cited by 290
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc
Yang, W., Shen, J., Wu, M., Arsura, M., FitzGerald, M., Suldan, Z., Kim, D. W., Hofmann, C. S., Pianetti, S., Romieu-Mourez, R., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204245 · Cited by 277
Dubik, D., Dembinski, T. C., & Shiu, R. P. C. (1987) · PubMed · Cited by 276
Notch signaling and inherited disease syndromes
Gridley, T. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg052 · Cited by 275
Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10257 · Cited by 268
c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Prall, O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4499 · Cited by 267
The Ins and Outs of MYC Regulation by Posttranslational Mechanisms
Vervoorts, J., Lüscher-Firzlaff, J., & Lüscher, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600017200 · Cited by 260
Bièche, I., Laurendeau, I., Tozlu, S., Olivi, M., Vidaud, D., Lidereau, R., & Vidaud, M. (1999) · PubMed · Cited by 254
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251
c-myc Is a Downstream Target of the Smad Pathway
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K., & Kato, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104170200 · Cited by 244
Butt, A. J., McNeil, C. M., Musgrove, E. A., & Sutherland, R. L. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00993 · Cited by 244
CRD-BP mediates stabilization of βTrCP1 and c-myc mRNA in response to β-catenin signalling
Noubissi, F. K., Elcheva, I., Bhatia, N., Shakoori, A., Ougolkov, A., Liu, J., Minamoto, T., Ross, J., Fuchs, S. Y., & Spiegelman, V. S. (2006) · Nature · doi:10.1038/nature04839 · Cited by 243
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells
Wang, Q., Zhang, H., Kajino, K., & Greene, M. I. (1998) · Oncogene · doi:10.1038/sj.onc.1202403 · Cited by 243
Schlange, T., Matsuda, Y., Lienhard, S., Huber, A., & Hynes, N. E. (2007) · Breast Cancer Research · doi:10.1186/bcr1769 · Cited by 229
Frederick, J. P., Liberati, N. T., Waddell, D. S., Shi, Y., & Wang, X.-F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2546-2559.2004 · Cited by 221
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Offit, K., Foulkes, W. D., Robson, M. E., Wacholder, S., Eng, C. M., Karp, S. E., & Begg, C. B. (2001) · PubMed · Cited by 218
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
The Role of the BRCA1 Tumor Suppressor in DNA Double-Strand Break Repair
Zhang, J., & Powell, S. N. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0192 · Cited by 209
Klinakis, A., Szabolcs, M., Politi, K., Kiaris, H., Artavanis-Tsakonas, S., & Efstratiadis, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603371103 · Cited by 207
Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
Venkitaraman, A. R. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151422 · Cited by 203
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200
Wilson, C. A., Payton, M. N., Elliott, G. S., Buaas, F. W., Cajulis, E. E., Grosshans, D., Ramos, L., Reese, D. M., Slamon, D. J., & Calzone, F. J. (1997) · Oncogene · doi:10.1038/sj.onc.1200924 · Cited by 193
Park, K.-J., Krishnan, V., O’Malley, B. W., Yamamoto, Y., & Gaynor, R. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.006 · Cited by 193
Watson, P. H., Pon, R. T., & Shiu, R. P. C. (1991) · PubMed · Cited by 177
Burness, M. L., Grushko, T. A., & Olopade, O. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24fc1 · Cited by 176
Self-citationLiu, M., Casimiro, M. C., Wang, C., Shirley, L. A., Jiao, X., Katiyar, S., Ju, X., Li, Z., Yu, Z., Zhou, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910009106 · Cited by 171
Le, X., Pruefer, F., & Bast, R. C. (2004) · Cell Cycle · doi:10.4161/cc.4.1.1360 · Cited by 170
Wei, M., Grushko, T. A., Dignam, J., Hagos, F., Nanda, R., Sveen, L., Xu, J., Fackenthal, J., Tretiakova, M., Das, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1277 · Cited by 170
Self-citationJeffries, S., Robbins, D. J., & Capobianco, A. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3927-3941.2002 · Cited by 169
Estrogen regulation of cell cycle progression in breast cancer cells
Prall, O. W. J., Rogan, E. M., & Sutherland, R. L. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00021-1 · Cited by 166
Matsuda, Y., Schlange, T., Oakeley, E. J., Boulay, A., & Hynes, N. E. (2009) · Breast Cancer Research · doi:10.1186/bcr2317 · Cited by 166
MYC in breast tumor progression
Chen, Y., & Olopade, O. I. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1689 · Cited by 164
Self-citationBlancato, J., Singh, B., Liu, A., Liao, D. J., & Dickson, R. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601703 · Cited by 160
Key signalling nodes in mammary gland development and cancer: Myc
Hynes, N. E., & Stoelzle, T. (2009) · Breast Cancer Research · doi:10.1186/bcr2406 · Cited by 159
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 156
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo
Wang, Y., Liu, S., Zhang, G., Zhou, C., Zhu, H., Zhou, X., Quan, L., Bai, J., & Xu, N. (2004) · Breast Cancer Research · doi:10.1186/bcr975 · Cited by 151
Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients
López‐Knowles, E., Zardawi, S. J., McNeil, C. M., Millar, E. K. A., Crea, P., Musgrove, E. A., Sutherland, R. L., & O'Toole, S. A. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0741 · Cited by 150
Reversible Smad-Dependent Signaling between Tumor Suppression and Oncogenesis
Sekimoto, G., Matsuzaki, K., Yoshida, K., Mori, S., Murata, M., Seki, T., Matsui, H., Fujisawa, J., & Okazaki, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4629 · Cited by 146
Li, H., Lee, T., & Avraham, H. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112231200 · Cited by 134
BRCA1 methylation: a significant role in tumour development?
Catteau, A., & Morris, J. R. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00056-1 · Cited by 122
Mukherjee, S., & Conrad, S. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502278200 · Cited by 120
Cowling, V. H., D’Cruz, C. M., Chodosh, L. A., & Cole, M. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02282-06 · Cited by 118
The Axin1 scaffold protein promotes formation of a degradation complex for c‐Myc
Arnold, H., Zhang, X., Daniel, C. J., Tibbitts, D., Escamilla‐Powers, J. R., Farrell, A., Tokarz, S. A., Morgan, C. W., & Sears, R. C. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.279 · Cited by 117
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 112
Alles, M. C., Gardiner‐Garden, M., Nott, D. J., Wang, Y., Foekens, J. A., Sutherland, R. L., Musgrove, E. A., & Ormandy, C. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004710 · Cited by 109
MYC Is Amplified in BRCA1 -Associated Breast Cancers
Grushko, T. A., Dignam, J. J., Das, S., Blackwood, A. M., Perou, C. M., Ridderstråle, K., Anderson, K. N., Wei, M.-J., Adams, A. J., Hagos, F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0976-03 · Cited by 103
Self-citationMusgrove, E. A., Sergio, C. M., Loi, S., Inman, C. K., Anderson, L. R., Alles, M. C., Pinese, M., Caldon, C. E., Schütte, J., Gardiner‐Garden, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002987 · Cited by 101
Lack of Cyclin-Dependent Kinase 4 Inhibits c- myc Tumorigenic Activities in Epithelial Tissues
de Marval, P. L. M., Macias, E., Rounbehler, R. J., Siciński, P., Kiyokawa, H., Johnson, D. G., Conti, C. J., & Rodríguez‐Puebla, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7538-7547.2004 · Cited by 101
HER2 as a target for breast cancer therapy
Tagliabue, E., Balsari, A., Campiglio, M., & Pupa, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689972 · Cited by 95
Robanus-Maandag, E. C., Bosch, C. A. J., Kristel, P., Hart, A. A. M., Faneyte, I. F., Nederlof, P. M., Peterse, J. L., & van de Vijver, M. J. (2003) · The Journal of Pathology · doi:10.1002/path.1385 · Cited by 93
BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene
Kennedy, R. D., Gorski, J. J., Quinn, J. E., Stewart, G. E., James, C. R., Moore, S., Mulligan, K., Emberley, E. D., Lioe, T. F., Morrison, P. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1841 · Cited by 88
Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer.
Jeruss, J. S., Sturgis, C. D., RADEMAKER, A. W., & Woodruff, T. K. (2003) · PubMed · Cited by 87
Efstratiadis, A., Szabolcs, M. J., & Klinakis, A. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3838 · Cited by 84
Carroll, J. S., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2002) · PubMed · Cited by 83
Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.
Doyle, G. A. R., Bourdeau-Heller, J. M., Coulthard, S., Meisner, L. F., & Ross, J. (2000) · Cancer Research · Cited by 82
Role of BRCAgene dysfunction in breast and ovarian cancer predisposition
Scully, R. (2000) · Breast Cancer Research · doi:10.1186/bcr76 · Cited by 81
Fujii, Y., Yada, M., Nishiyama, M., Kamura, T., Takahashi, H., Tsunematsu, R., Susaki, E. A., Nakagawa, T., Matsumoto, A., & Nakayama, K. I. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00239.x · Cited by 72
Schlotter, C. M., Vogt, U., Bosse, U., Mersch, B., & Waβmann, K. (2003) · Breast Cancer Research · doi:10.1186/bcr568 · Cited by 71
Naidu, R., Wahab, N. A., Yadav, M., & Kutty, M. (2002) · International Journal of Molecular Medicine · doi:10.3892/ijmm.9.2.189 · Cited by 70
You, Z., Madrid, L. V., Saims, D., Sedivy, J. M., & Wang, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203213200 · Cited by 70
Venditti, M., Iwasiow, B. M., Orr, F. W., & Shiu, R. P. C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10269 · Cited by 69
TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein
Andaloussi, S. E., Johansson, H. J., Magnúsdóttir, A., Järver, P., Lundberg, P., & Langel, Ü. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.012 · Cited by 68
The Influence of Basal Phenotype on the Metastatic Pattern of Breast Cancer
Luck, A. A., Evans, A. J., Green, A. R., Rakha, E. A., Paish, C. E., & Ellis, I. O. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.10.002 · Cited by 68
Chrzan, P., Skokowski, J., Karmoliński, A., & Pawełczyk, T. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00260-0 · Cited by 63
Park, K., Kwak, K., Kim, J., Lim, S., & Han, S. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.04.016 · Cited by 63
E-cadherin repression contributes to c-Myc-induced epithelial cell transformation
Cowling, V. H., & Cole, M. D. (2006) · Oncogene · doi:10.1038/sj.onc.1210132 · Cited by 62
Sulindac suppresses β-catenin expression in human cancer cells
Han, A., Song, Z., Tong, C., Hu, D. G., Bi, X., Augenlicht, L. H., & Yang, W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.034 · Cited by 61
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
MYC amplification in breast cancer: a chromogenic in situ hybridisation study
Rodríguez-Pinilla, S. M., Jones, R. L., Lambros, M. B. K., Arriola, E., Savage, K., James, M., Pinder, S. E., & Reis-Filho, J. S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043869 · Cited by 59
Ioannidis, P., Mahaira, L. G., Papadopoulou, A., Teixeira, M. R., Heim, S., Andersen, J. A., Εvangelou, Ε., Dafni, U. G., Pandis, N., & Trangas, T. T. (2003) · International Journal of Cancer · doi:10.1002/ijc.10794 · Cited by 59
Targeting oncogenes to improve breast cancer chemotherapy.
Christensen, L. A., Finch, R., Booker, A. J., & Vasquez, K. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4288 · Cited by 59
Carbone, G. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh527 · Cited by 57
c- myc Amplifications in primary breast carcinomas and their local recurrences
Aulmann, S., Adler, N., Rom, J., Helmchen, B., Schirmacher, P., & Sinn, H. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.029264 · Cited by 56
Sasaki, T., Suzuki, H., Yagi, K., Furuhashi, M., Yao, R., Susa, S., Noda, T., Arai, Y., Miyazono, K., & Kato, M. (2003) · PubMed · Cited by 55
The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma
Corzo, C., Corominas, J. M., Tusquets, I., Salido, M., Bellet, M., Fabregat, X., Serrano, S., & Solé, F. G. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.08.013 · Cited by 53
Xiao, L., McWatters, A., Wiener, J. R., Wu, J. Y., Mills, G. B., & Bast, R. C. (2000) · PubMed · Cited by 52
Janocko, L. E., Brown, K. A., Smith, C. A., Gu, L. P., Pollice, A. A., Singh, S. G., Julian, T. B., Wolmark, N., Sweeney, L., Silverman, J. F., et al. (2001) · Cytometry · doi:10.1002/cyto.1098 · Cited by 48
Rummukainen, J. K., Salminen, T. M., Lundin, J. E., et al. (2001) · Modern Pathology · doi:10.1038/modpathol.3880431 · Cited by 47
C-myc oncogene amplification in ductal carcinoma in situ of the breast
Aulmann, S., Bentz, M., & Sinn, H. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016061327812 · Cited by 42
Basal-like subtype and BRCA1 dysfunction in breast cancers
Miyoshi, Y., Murase, K., & Oh, K. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0831-x · Cited by 39
Moon, D., Kim, M.-O., Heo, M., Lee, J.-D., Choi, Y. H., & Kim, G. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-2002-7 · Cited by 39
Ramljak, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00135-6 · Cited by 38
Hines, W. C., Fajardo, A. M., Joste, N. E., Bisoffi, M., & Griffith, J. K. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0031 · Cited by 38
Dadiani, M., Seger, D., Kreizman, T., Badikhi, D., Margalit, R., Eilam, R., & Degani, H. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0249 · Cited by 38
Myc stabilization in response to estrogen and phospholipase D in MCF‐7 breast cancer cells
Rodrik-Outmezguine, V. S., Gomes, E., Li, H., Rockwell, P., & Foster, D. A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.09.013 · Cited by 28
Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer
Mullan, P. B., & Millikan, R. C. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7389-z · Cited by 24
Characterization of a novel trastuzumab resistant human breast cancer cell line
Balazs, M. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e119 · Cited by 8
High-Throughput Screening Compatible Cell-Based Assay for Interrogating Activated Notch Signaling
Hancock, M. K., Kopp, L., & Bi, K. (2009) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.173 · Cited by 5
Cited by
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
A Multicolor Nanoprobe for Detection and Imaging of Tumor‐Related mRNAs in Living Cells
Li, N., Chang, C., Pan, W., & Tang, B. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203767 · Cited by 321
Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.09.001 · Cited by 154
Alignment of spatial genomics data using deep Gaussian processes
Jones, A., Townes, F. W., Li, D., & Engelhardt, B. E. (2023) · Nature Methods · doi:10.1038/s41592-023-01972-2 · Cited by 85
Metadata
- Authors
- Xu, J., Chen, Y., & Olopade, O. I.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2010-06-01
- Volume
- 1
- Issue
- 6
- Pages
- 629-640
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2123734813
- Cited by
- 382
- References
- 164
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.